Drug giant GlaxoSmithKline (NYSE: GSK) has finalized a $750 million settlement with the U.S. government that centered around an investigation of GSK’s former pharmaceutical production plant in Cidra, Puerto Rico.

An agreement in principal was

GSK said the amount of the settlement had not changed.

“This settlement resolves a significant and long-standing legal issue facing the company,” said PD Villarreal, GSK’s head of global litigation, in a statement.

"We regret that we operated the Cidra facility in a manner that was inconsistent with current Good Manufacturing Practice (cGMP) requirements and with GSK’s commitment to manufacturing quality,” he added. “GSK worked hard to resolve fully the manufacturing issues at the Cidra facility prior to its closure in 2009 and we are committed to continuous improvement in our manufacturing processes. Our commitment to compliance with cGMP is demonstrated by the fact that we have not received an FDA warning letter at any plant since the Cidra facility was cited in July 2002.”

GSK closed the plant last year and no longer owns the facility.

GSK operates its U.S. headquarters in RTP and employs some 5,000 people in the area.

Get the latest news alerts: at Twitter.